How these two FDA-approved GLP-1 weight-loss medications differ — and how a physician chooses.
Medically reviewed by Charles Kamen, MD, board-certified neurologist
Semaglutide and tirzepatide are both FDA-approved medications used in medical weight management, but they work through different hormone pathways. Patients often ask which is "better" — the honest answer is that the right choice depends on your medical history, response, and goals.
At LiveNow Longevity, Dr. Charles Kamen, MD reviews your labs and history before recommending either. Below is an educational comparison; it is not medical advice or a substitute for evaluation.
Bottom line: Both are FDA-approved and effective for many patients. Tirzepatide acts on an additional hormone pathway; semaglutide is the longer-established option. Which is right for you is a medical decision made after evaluation — not a one-size answer.
Neither is universally "better." Tirzepatide acts on two hormone pathways (GIP and GLP-1) while semaglutide acts on one (GLP-1). The right choice depends on your history, response, and goals, determined by Dr. Kamen after evaluation.
Yes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved. We prescribe FDA-approved options after a complete medical evaluation when appropriate.
That is exactly what the medical evaluation is for. Dr. Kamen reviews your labs and history and recommends the option that fits your situation — or a different approach if more appropriate.
Book online or call (702) 808-2650 to schedule your evaluation in Las Vegas.
Physician-Led in Las Vegas
That is a medical decision — and exactly what the $88 evaluation is for. Dr. Charles Kamen, MD reviews your labs, history, and goals and recommends the option that fits you.
Schedule a consultation with Dr. Kamen today.
Book Your Consultationphysician-led peptide therapy Las Vegas — visit our clinic